Skip to content

Santa Ana, CA, March 24, 2021 – FlemingMartin, LLC is pleased to announce that NKGen Biotech, a biotechnology company committed to harnessing the power of the body’s immune system via the development of unique natural killer (NK) cell therapies, has hired Philip “Phil” Moody as their Chief Financial Officer.

Phil brings over 25 years of financial strategy, capital raising, investor relations, and operations leadership in the life sciences industry to NKGen Biotech. He possesses a deep passion for building finance teams while guiding strategy for ascending businesses on the leading edge of innovation. Previously, Phil served as CFO at PaxVax, a specialty vaccine company, and he helped drive PaxVax to a successful acquisition by Emergent BioSolutions. Before PaxVax, at BTG plc, Phil served as Chief Financial Officer for all of North America at the British-based medical device/specialty pharma company (since acquired by Boston Scientific). Prior to BTG, Phil spent more than a decade at Chiron Corporation (purchased by Novartis), where he rose to the position of CFO for the Biopharmaceuticals division.

Phil earned his Bachelor of Science in Mechanical Engineering from the University of California, Berkeley.

Nkgen Biotech 2NKGen Biotech is dedicated to improving outcomes in cancer, autoimmune disease, and neurodegeneration by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.



Fleming Martin Color Logo Medium 72 Ppi 300X65 1FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.